The 900 MHz bid is still there


Anterix still has the kind of asset that keeps drawing attention even when the stock cools off. It owns the largest licensed position in the U.S. 900 MHz band, and that matters because utilities do not buy this name for a story about app downloads or consumer churn. They buy it for private LTE and 5G-ready networks that can carry grid operations, outage response, and the sort of resilient communications infrastructure that looks dull until the lights go out.
The sector backdrop helps. Utility modernization is not a slogan here, it is the commercial reason the stock exists. Distributed energy resources, outage management, and the push for secure connectivity have kept low-band spectrum in the conversation, while the FCC’s February 2026 order expanding the broadband segment to 10 MHz gave the market a cleaner path for larger deployments. The bull case is straightforward: scarce spectrum, a narrow use case, and a customer base that values reliability over fashion.
The market had already been paying up for the scarcity angle. In early September, ATEX was trading around $82 to $85 after a sharp year-to-date advance, and the name had spent the year benefiting from the same broad theme that has lifted other infrastructure and spectrum assets. When a company controls a constrained band and can point to utility contracts, the market tends to give it more time than it gives a normal telecom small cap.
That premium is not built on one customer. Recent agreements cited in the research include CPS Energy, Texas-New Mexico Power, NorthWestern Energy, and Benton PUD. Those names matter because they show the business is not just a slide deck about future demand. It is a real deployment pipeline, and the company has been able to keep the utility narrative alive while the broader market keeps rotating between growth, duration, and hard-asset proxies.
The comparison set also frames the valuation debate. American Tower, Crown Castle, and SBA Communications trade on infrastructure economics, but Anterix is not a tower REIT in disguise. Its model is smaller, more concentrated, and more dependent on the monetization of a single spectrum position. That makes the upside more levered if the utility buildout keeps moving, and it also makes the stock easier to re-rate when the market starts asking how many of those deals turn into recurring economics rather than one-off headlines.
The other reason the stock had room to run is that spectrum scarcity has become a live market theme again. High-profile transactions elsewhere in wireless have reminded the market that low-band spectrum is not easy to replace, and management has leaned on that fact when positioning the company’s holdings. If you own the rare asset, you get to talk about replacement cost. If you do not, you pay it.
The filing that matters here is not just one sale. It is the pattern around it. On September 11, Chief Legal Officer and Corporate Secretary Gena L. Ashe reported two sales, one worth roughly EUR 298,477 and another worth EUR 21,519, both euro-normalised at ingest. Earlier in September, the same executive had already sold 4,357 shares at $85.44 each for about $372,000, and the broader September tape included other insider disposals as well.
That is the part the bull case has to absorb. The company was not in distress, the stock was not collapsing, and the sales were not happening after a disastrous quarter. They came after a strong run, into a name that had already been rewarded for its spectrum story. That does not make the sales sinister. It does make them relevant. Insiders do not need to be panicked to sell, and they do not need to be wrong to trim. But when several filings land in the same direction over a short window, you stop treating them as noise.
Our internal cluster read reflects that. InsiderTrades data shows five distinct insiders trading the name in the same direction over the past quarter, with 12 recent declarations in the cluster picture. The score rationale leans on that breadth, on the filing size relative to market value, and on the fact that the transaction value was near EUR 298,477. That is not a giant print in absolute terms for a company with a market value of about EUR 1.56 billion, but it is not pocket change either. It is a real sale by an executive who sits inside the legal and corporate secretary function, not a symbolic odd-lot.
The strongest version of the long case is easy to write. Anterix owns scarce spectrum. Utilities need secure private networks. The FCC has been more accommodating. The customer list is growing. The stock has already shown it can rerate when the market believes the monetization path is getting clearer. That is the clean story, and it is why the name has attracted attention from analysts who remain constructive on the scarcity premium and the pipeline.
The catch is that the business still has a visibility problem. The post-earnings backdrop matters here. The company’s fiscal Q1 2027 report showed spectrum-driven revenue growth to $1.96 million, but the market also had to sit with limited recurring GAAP revenue visibility. That is the tension in the name. The asset is real, the demand is real, but the cadence of monetization is still lumpy enough that the stock can move faster than the underlying revenue base.
The balance sheet helps, and it helps a lot. The company is debt-free and had cash above $116 million, which gives management room to keep pushing the utility strategy without the kind of financing pressure that usually distorts a small-cap telecom story. But cash does not solve the central question. How quickly do spectrum agreements turn into durable economics, and how much of the market cap is already discounting that answer? When a stock has already had a multi-hundred-percent year-to-date move, the burden shifts from proving the asset exists to proving the monetization can keep up with the price.
That is where the insider sales bite a little harder. They do not break the thesis. They do not even necessarily weaken it in a fundamental sense. They do, however, tell you that at least some of the people nearest the filing calendar were willing to sell into strength rather than wait for a cleaner breakout. In a name this dependent on narrative and policy, that is a useful reminder that the market can get ahead of the cash flow.

InsiderTrades data gives you a useful historical frame, but only if you keep it in its lane. The relevant bucket here is director-level buys at mid-cap names, with a sample size of 5,294. That cohort posted a 54.2% 90-day win rate and a 5.9% average 90-day return. Again, that is historical cohort data, not a forecast for ATEX, and it is not a promise that a sale cluster here will resolve the same way as a buy cluster elsewhere.
The point of the cohort read is narrower. It tells you that director-level activity at mid-cap names has not been random in our historical sample. It has had enough signal content to be worth tracking, especially when the filing sits inside a broader cluster and the stock is already extended. But the direction matters. This is a selling cluster, not a buying one, so you should not lazily import the cohort’s buy-side history and pretend it blesses the current setup. It does not.
The internal score framework is consistent with that caution. The company’s fundamental score sits at 58, with a quality rank of 10,533 out of 29,064 and a quality subscore of 67. That is not a disaster profile, and it is not a screaming quality compounder either. It is a middling-to-decent operating profile wrapped around a scarce asset. The market can pay for that. It can also get impatient with it.
The stock’s recent path matters because it changes the burden of proof. ATEX had already softened in the near term, with a roughly 11% one-month decline and some five-day weakness after the earlier run. That does not erase the year-to-date move, but it does mean the insider sales were not printed into a fresh euphoric spike. They landed after the market had already started to cool the name.
That makes the tape less forgiving and the stock more interesting. If the shares were still accelerating, you could dismiss the filings as routine de-risking into strength. If the shares were breaking down, you would read them as confirmation of a broken story. Here, you get the awkward middle. The long case is still alive, but the market has stopped paying for it as aggressively as it did in the first half of the run.
The peer set reinforces that awkwardness. Tower names and infrastructure assets can trade on yield, lease-up, and long-duration cash flows. Anterix trades on a narrower proposition, one that depends on policy, spectrum scarcity, and utility adoption. That can produce violent upside when the market believes the path is opening. It can also produce sharp air pockets when the market decides the next contract is taking too long.
There is also a reason the stock can stay expensive even after a pullback. The company’s position in 900 MHz is not easy to replicate, and the FCC backdrop has been friendlier than it was a few years ago. The market knows that. So do the insiders. That is why the sales matter more than they would in a generic telecom name. They are happening in a stock whose valuation already leans on a scarcity premium.
If you want the bull case in one sentence, it is this: Anterix owns a scarce spectrum asset, the utility use case is real, and the policy backdrop has improved enough to keep the monetization story alive. That is a legitimate setup, and it is why analysts have stayed constructive even after the stock’s strong run.
If you want the catch, it is equally simple. The company still has limited recurring GAAP revenue visibility, the stock has already done a lot of the rerating work, and the September filings show insiders taking money off the table in a cluster rather than waiting for a cleaner proof point. The sales do not invalidate the thesis, but they do tell you that the easy part of the trade may already be behind it.
Our strategy headline, for what it is worth, remains a live placeholder rather than a promise, and it sits inside a restricted EU venue universe with a short, single-regime window. The framework is useful as a screen, not as a guarantee of what ATEX will do next. That matters because this is exactly the kind of name where a neat backtest can seduce you into forgetting the real driver is still policy, customer adoption, and timing.
So the honest read is not to chase the sales as if they were a smoking gun, and not to ignore them as if they were routine footnotes. The company still has a credible asset story, the sector still has a bid, and the stock still has room to move if utility deployments keep landing. But the September cluster says the executives filing the forms were willing to sell into strength, and the next real test is whether the company can turn the FCC backdrop and the customer list into more than another round of scarcity talk.
The next filing window, the next utility agreement, and the next update on recurring revenue will matter more than the last sale.
The filing trail for the September 11 sales is in the SEC-linked Form 4 materials and the related insider-trading summaries. The business backdrop comes from the company’s annual report, recent earnings coverage, and sector reporting on 900 MHz spectrum, FCC policy, and utility private-network demand.
The point is not that one source settles the trade. It is that the filings arrived against a live sector story, a stock that had already rerated, and a company whose next proof point is still operational rather than cosmetic.
Dig deeper: Anterix Inc.'s full insider filing history.
This is not investment advice.
AstraZeneca rose on mixed oncology data, with SERENA-4 missing and Enhertu and Tagrisso helping. Insider activity remain...
Delek director Vicky Sutil sold EUR 393,580 under a 10b5-1 plan while refining margins stay hot and peers keep ripping h...
Prudential directors bought shares on 10 September after H1 2026 results. Here is how the cluster reads against Asia ins...
Henlius directors sold a small EUR 16.3k cluster while Hong Kong biotech bounced. The stock still trails YTD, and the fi...
Ridley directors bought after a fertilizer-led reset, with the stock around A$2.60 and peers still trading on weather, m...
Three Sabre directors bought through the SIP on 10 September. The catch is the UK motor cycle is still softening, and th...